

Supplement Table 1 Effects of Early and Late intervention by PC945 on fungal load (CFU) in lung and galactomannan concentrations in BALF and serum in *Aspergillus fumigatus* infected, immuno-compromised, neutropenic mice

Treatment Regimen	N	Dose $\mu\text{g}/\text{mouse}$ [mg/kg]	Values (% inhibition of response)		
			CFU (mg of lung)	GM in BALF (COI)	GM in serum (COI)
Vehicle + Conidia	5	None	28.4 \pm 16.9	4.8 \pm 0.40	5.3 \pm 1.1
Early Intervention	6	2.8 [0.14]	15.2 \pm 13.7 (46)	0.70 \pm 0.39 (85)	0.81 \pm 0.52 (85)
	6	14 [0.70]	2.1 \pm 1.6 (93)	0.37 \pm 0.46 (92)	0.24 \pm 0.18 (95)
	6	70 [3.5]	0.8 \pm 0.7 (97)	0.13 \pm 0.02 (97)	0.18 \pm 0.07 (97)
Late Intervention	6	14 [0.70]	3.8 \pm 1.0 (87)	0.24 \pm 0.06 (95)	0.29 \pm 0.11 (95)
	6	70 [3.5]	1.9 \pm 1.7 (93)	0.22 \pm 0.14 (95)	0.25 \pm 0.19 (95)
	6	350 [17.5]	0.5 \pm 0.3 (98)	0.11 \pm 0.05 (98)	0.24 \pm 0.11 (95)

BALF=bronchoalveolar lavage fluid; CFU=colony forming units; COI: cut-off index which was calculated by the formula: Cut-off index=OD in sample / OD in cut-off control provided in kit; GM=galactomannan; N=number.

Data for fungal load and GM are shown as the mean \pm standard error (SD); N=5–6.

Percentage inhibition with respect to vehicle (shown in brackets).

Supplement Table 2 Effects of Early and Late intervention by PC945 on macrophage and neutrophil accumulation into the BALF, IFN γ , IL-17 and MDA levels in the BALF and IL-6 and TNF α levels in the serum of *Aspergillus fumigatus* infected, immuno-compromised, neutropenic mice

Treatment Regimen	N	Dose $\mu\text{g}/\text{mouse}$ [mg/kg]	Cell numbers in BAL $\times 10^5/\text{mL}$ (% inhibition)		Biomarkers in BALF (% Inhibition)			Biomarkers in serum (% Inhibition)	
			Macrophage	Neutrophil	IFN γ (pg/mL)	IL-17 (pg/mL)	MDA ($\mu\text{g}/\text{mL}$)	IL-6 (pg/mL)	TNF α (pg/mL)
Vehicle + Conidia	5	None	0.65 \pm 0.14	0.49 \pm 0.09	9.2 \pm 1.0	19.8 \pm 3.6	1.8 \pm 0.2	284 \pm 112	25.6 \pm 8.0
	6	2.8 [0.14]	0.40 \pm 0.15 (38)	0.37 \pm 0.04 (24)	3.7 \pm 1.7 (60)	9.8 \pm 5.3 (51)	0.96 \pm 0.32 (47)	159 \pm 73.3 (44)	11.8 \pm 5.9 (54)
	6	14 [0.70]	0.32 \pm 0.07 (51)	0.26 \pm 0.12 (47)	3.0 \pm 0.8 (67)	6.7 \pm 4.9 (66)	0.57 \pm 0.22 (68)	86.3 \pm 46.9 (70)	7.3 \pm 3.5 (71)
Early Intervention	6	70 [3.5]	0.26 \pm 0.05 (60)	0.22 \pm 0.04 (55)	2.5 \pm 0.3 (73)	3.2 \pm 0.8 (84)	0.34 \pm 0.05 (81)	44.5 \pm 12.2 (84)	4.7 \pm 0.4 (82)
	6	14 [0.70]	0.43 \pm 0.05 (34)	0.38 \pm 0.04 (22)	4.3 \pm 2.2 (53)	8.5 \pm 2.9 (57)	0.45 \pm 0.10 (75)	51.7 \pm 16.8 (82)	6.2 \pm 0.5 (76)
	6	70 [3.5]	0.40 \pm 0.11 (38)	0.34 \pm 0.05 (31)	3.3 \pm 0.8 (64)	4.0 \pm 0.8 (80)	0.37 \pm 0.10 (79)	44.2 \pm 11.4 (84)	5.5 \pm 0.7 (79)
Late Intervention	6	350 [17.5]	0.32 \pm 0.07 (51)	0.27 \pm 0.08 (45)	2.1 \pm 0.3 (77)	2.9 \pm 0.7 (85)	0.25 \pm 0.05 (86)	35.9 \pm 10.4 (87)	4.9 \pm 0.6 (81)

BALF=bronchoalveolar lavage fluid; IFN γ =interferon gamma; IL-17=interleukin 17; MDA=malondialdehyde.N=number. The data are shown as the mean \pm standard error (SD); N=5–6. Percentage inhibition with respect to vehicle.

Supplement Table 3 Effects of Early and/or Late intervention by posaconazole or voriconazole on fungal load (CFU) in lung and galactomannan concentrations in BALF and serum in *Aspergillus fumigatus* infected, immuno-compromised, neutropenic mice

Treatment Regimen	N	Dose $\mu\text{g}/\text{mouse}$ [mg/kg]	Values (% inhibition of response)		
			CFU (mg of lung)	GM in BALF (COI)	GM in serum (COI)
(Posaconazole)					
Vehicle + Conidia	5	None	21.0 \pm 7.3	3.4 \pm 0.40	3.7 \pm 0.4
Early Intervention	6	2.8 [0.14]	13.8 \pm 9.7 (34)	4.4 \pm 0.9 (-29)	3.0 \pm 0.60 (19)
	6	14 [0.70]	9.5 \pm 6.3 (55)	3.5 \pm 1.4 (-3)	2.0 \pm 1.3 (46)
	6	70 [3.5]	1.6 \pm 0.9 (92)	0.6 \pm 0.3 (82)	0.3 \pm 0.2 (92)
(Posaconazole)					
Vehicle + Conidia	5	None	18.7 \pm 15.2	3.7 \pm 1.1	3.6 \pm 1.1
Late Intervention	6	14 [0.70]	9.2 \pm 12.9 (51)	2.6 \pm 0.5 (30)	2.7 \pm 0.7 (25)
	6	70 [3.5]	1.5 \pm 1.0 (83)	0.6 \pm 0.4 (84)	0.4 \pm 0.2 (89)
	6	350 [17.5]	0.4 \pm 0.3 (98)	0.2 \pm 0.1 (95)	0.1 \pm 0.0 (97)
(Voriconazole)					
Vehicle + Conidia	5	None	23.9 \pm 10.5	5.9 \pm 0.1	4.7 \pm 0.9
Early Intervention	6	70 [3.5]	20.6 \pm 8.3 (14)	4.5 \pm 1.6 (24)	2.2 \pm 1.3 (53)
	6	350 [17.5]	9.7 \pm 1.1 (59)	3.2 \pm 1.3 (46)	2.3 \pm 1.2 (51)
	6	1050 [52.5]	4.9 \pm 1.9 (79)	1.0 \pm 0.4 (83)	0.5 \pm 0.2 (89)


BALF=bronchoalveolar lavage fluid; CFU=colony forming units; COI: cut-off index which was calculated by the formula: Cut-off index=OD in sample / OD in cut-off control provided in kit; GM=galactomannan; N=number.

Data for fungal load and GM are shown as the mean \pm standard error (SD); N=5–6.


Percentage inhibition with respect to vehicle (shown in brackets).

Supplement Figure 1

A



B



Relative cytokine concentrations in culture supernatant from PBMCs obtained from a healthy subject and stimulated with CytoMix. PC945 or dexamethasone were treated 2hrs before CytoStim stimulation and samples were collected 24hrs post stimulation. Cytokine levels were determined using MSD V-PLEX Plus Human Cytokine 30-Plex Kit and plotted as the value was expressed as log, ratio of the level of cytokines in the presence of drug with that in DMSO control, * $p < 0.001$.